Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hypochlorous Acid Based SPX-069
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SPX-001 is SpectrumX’s nebulised respiratory infection drug candidate, based on the Company’s licensed hypochlorous acid (HOCl)-based SPC-069 drug substance, which is believed to have broad-spectrum antipathogenic properties.
Brand Name : SPX-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 24, 2022
Lead Product(s) : Hypochlorous Acid Based SPX-069
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SPX-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Details : Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001.
Brand Name : SPX-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : SPX-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SpectrumX has confirmed scientific advice meeting with MHRA and will discuss the available data supporting the commencement of human trials with SPX-001 (Hypochlorous Acid) protocol for Phase Ib human volunteer study, prior to submission of CTA submissio...
Brand Name : SPX-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
Details : SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.
Brand Name : SPX-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : Hypochlorous Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?